Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The importance of microglia in most neurodegenerative pathologies, from Parkinson's disease to amyotrophic lateral sclerosis and Alzheimer's disease, is increasingly recognized. Until few years ago, microglial activation in pathological conditions was considered dangerous to neurons due to its causing inflammation. Today we know that these glial cells also play a crucial physiological and neuroprotective role, which is altered in neurodegenerative conditions. AREAS COVERED: The neuroinflammatory hypothesis for neurodegenerative diseases has led to the trial of anti-inflammatory agents as therapeutics with largely disappointing results. New information about the physiopathological role of microglia has highlighted the importance of immunomodulation as a potential new therapeutic approach. This review summarizes knowledge on microglia as a potential therapeutic target in the most common neurodegenerative diseases, with focus on compounds directed toward the modulation of microglial immune response through specific molecular pathways. EXPERT OPINION: Here we support the innovative concept of targeting microglial cells by modulating their activity, rather than simply trying to counteract their inflammatory neurotoxicity, as a potential therapeutic approach for neurodegenerative diseases. The advantage of this therapeutic approach could be to reduce neuroinflammation and toxicity, while at the same time strengthening intrinsic neuroprotective properties of microglia and promoting neuroregeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · cited 1×
“dent population of the brain, constitute about 5 – 20% of total brain cells displaying regional differences in density.[2] The traditional concept of microglial action in the brain was centered on the identification of these”
BackgroundNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Elmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., Kipnis, J., & Schwartz, M. (2006) · Nature Neuroscience · doi:10.1038/nn1629 · Cited by 1,209 · cited 2×
“ramified microglia as being in a resting state has been revised, based on the active role of resting microglia in development and plasticity.[6,12,13] On the other hand,”
BackgroundNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
CSF-1 receptor signaling in myeloid cells.
Stanley, E. R., & Chitu, V. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021857 · Cited by 825
Microglial cell dysregulation in brain aging and neurodegeneration
von Bernhardi, R., Eugenín-von Bernhardi, L., & Eugenín, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00124 · Cited by 556
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
Butovsky, O., Koronyo-Hamaoui, M., Kunis, G., Ophir, E., Landa, G., Cohen, H., & Schwartz, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604681103 · Cited by 388 · cited 1×
“Interestingly, this treatment induces microglial activation, microglial co-localization with β-amyloid fibrils and a phenotype switch in brain microglia toward cells producing insulin-like growth factor 1.[69] On the”
BackgroundWang, G., Shi, Y., Jiang, X., Leak, R. K., Hu, X., Wu, Y., Pu, H., Li, W.-W., Tang, B., Wang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501441112 · Cited by 376
Gao, H.-M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., & Hong, J.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3732-10.2011 · Cited by 369
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Microglia in ALS: The Good, The Bad, and The Resting
Henkel, J. S., Beers, D. R., Zhao, W., & Appel, S. H. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9171-5 · Cited by 353 · cited 1×
“sclerosis (ALS).[34] The availability of transgenic mouse models reproducing onset, time course and final ending of the human disease in a time period of few months, has encouraged animal studies based on a”
BackgroundInhibition of autoimmune encephalomyelitis by a tetracycline
Popovic, N., Schubart, A., Goetz, B. D., Zhang, S., Linington, C., & Duncan, I. D. (2002) · Annals of Neurology · doi:10.1002/ana.10092 · Cited by 295 · cited 4×
“[8] More recently, it has been observed that the microglial repopulation of the brain after depletion through the administration of a colony-stimulating factor 1 receptor (CSF1R) antagonist, which is a key regulator of myeloid lineage cells, is due to the proliferation of nestin-expressing CONTACT Barbara Monti b.mont…”
BackgroundInfluentialPioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
The choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276 · cited 1×
“tus mainly due to microglial activation.[56] However, the only published report on NSAID administration to an animal model of HD gave negative results,[57] while”
ResultNeuroprotective function for ramified microglia in hippocampal excitotoxicity
Vinet, J., van Weering, H. R., Heinrich, A., Kälin, R. E., Wegner, A., Brouwer, N., Heppner, F. L., van Rooijen, N., Boddeke, H. W., & Biber, K. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-27 · Cited by 274 · cited 1×
“additionally protect hippocampal neurons under these pathological conditions.[18] The novel understanding of microglial morphology and functions obviously ren-”
BackgroundChen, P. S., Wang, C.-C., Bortner, C. D., Peng, G.-S., Wu, X., Pang, H., Lu, R.-B., Gean, P.-W., Chuang, D.-M., & Hong, J.-S. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.06.053 · Cited by 262
Yuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240 · cited 1×
“inflammation and inflammation-induced neurotoxicity both directly and indirectly, through astrocytes.[100] In addition, by using GSK3β knockout mice, it has”
BackgroundSystemic inflammatory cells fight off neurodegenerative disease
Schwartz, M., & Shechter, R. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.71 · Cited by 240
Streit, W. J., & Xue, Q.-S. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9163-5 · Cited by 205
Biscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164 · cited 1×
“effect on the number and size of amyloid plaques and response to appropriate cognitive tests.[45,46] Notwithstanding a major limitation due to the fact”
BackgroundMizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.011 · Cited by 159 · cited 1×
“stimulation of their phagocytic activity.[11] Over time, the simple concept of ‘resting’ and ‘activated’ microglia has revealed itself increasingly inadequate to understand”
BackgroundNuclear Receptors License Phagocytosis by Trem2+Myeloid Cells in Mouse Models of Alzheimer's Disease
Savage, J. C., Jay, T., Goduni, E., Quigley, C., Mariani, M. M., Malm, T., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4586-14.2015 · Cited by 154 · cited 1×
“increase the expression of phagocytosis-related genes, such as TREM2, and enhance phagocytosis for plaque clearance in AD brains,[121] thus suggesting a role for”
BackgroundChen, S.-H., Oyarzabal, E. A., & Hong, J.-S. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.10.001 · Cited by 76
Cited by
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 375
Self-citationTargeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULK1
He, Y., She, H., Zhang, T., Xu, H., Cheng, L., Yepes, M., Zhao, Y., & Mao, Z. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201701049 · Cited by 287
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Cocaine-mediated downregulation of miR-124 activates microglia by targeting KLF4 and TLR4 signaling.
Periyasamy, P., Liao, K., Kook, Y. H., Niu, F., Callen, S. E., Guo, M.-L., & Buch, S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0584-5 · Cited by 128
Metadata
- Authors
- Peña-Altamira, E., Prati, F., Massenzio, F., Virgili, M., Contestabile, A., Bolognesi, M. L., & Monti, B.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2015-12-15
- Volume
- 20
- Issue
- 5
- Pages
- 627-640
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2175377156
- Cited by
- 69
- References
- 27
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.